Unknown PHASE2 INTERVENTIONAL 1-arm NCT04627363

HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama

HAIC Synchronously Combined With Bevacizumab and Toripalimab First-line for Advanced Hepatocellular Carcinama

Sponsor: Second Affiliated Hospital of Guangzhou Medical University

Conditions Bevacizumab Hepatocellular Carcinoma Liver Neoplasms Oxaliplatin Toripalimab

Interventions Bevacizumab Hepatic arterial infusion chemotherapy Toripalimab

Updated 5 times since 2020 Last updated: Nov 12, 2020 Started: Jan 1, 2021 Primary completion: Jun 30, 2022 Completion: Jun 30, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Bevacizumab and Hepatocellular Carcinoma, this trial is ongoing. The trial is conducted by Second Affiliated Hospital of Guangzhou Medical University and has accumulated 5 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Aug 2023 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Not Yet Recruiting → Unknown Status
Jan 2021 — Aug 2023 [monthly]

Not Yet Recruiting PHASE2
Dec 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Second Affiliated Hospital of Guangzhou Medical University
Sun Yat-sen University

Data source: Sun Yat-sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.